Dioxin analysis --- Xenobiotic Detection Systems (XDS) is a research based biotechnology company offering a patented unique, rapid, and economical bioassay for analyzing dioxin and dioxin-like compounds, including PCBs, dibenzodioxins, and dibenzofurans, with detection limits of less than one part per trillion. XDS has also developed reporter bioassay systems for endocrine disruptors. These systems identify estrogen agonists as well as antagonists by measuring receptor mediated transcriptional activation. This activity can be measured in pure compounds or in extracts.
XDS exists to develop and advance commercial acceptance of biological methods that will facilitate assessment of environmental and human health risks.
Dioxins are one of the most toxic man-made compounds known and are persistent contaminants in the environment. The term dioxins generally refer to a family of related chemical compounds that include the chlorinated dibenzo-p-dioxins and chlorinated dibenzofurans. Collectively, these groups of compounds belong to a class of compounds called polychlorinated diaromatic hydrocarbons (PCDH). PCDH have been extensively studied and are known to accumulate in animals causing toxic effects. Birth defects, immunotoxicity, tumor production, changes in metabolism and even death have all been observed as a result of exposure to PCDH.
Endocrine disrupting chemicals affect normal hormone responses in both humans and wildlife. Concern about these chemicals has increased worldwide as studies have suggested that these chemicals may be associated with global increases in testicular cancer, regional declines in sperm counts, altered sex ratios in wildlife populations, increases in the incidence of breast cancer and endometriosis, and accelerated puberty in females.
Xenobiotic Detection Systems (XDS) was started in 1995 by Drs. George C. Clark and Michael S. Denison. In 1997 XDS received major Research and Development funding from the National Institutes of Health for their dioxin analysis bioassay and their endocrine disruptor assay as well.
In 1998 XDS was awarded a U.S. patent (5,854,010) for its proprietary XDS-CALUX (Chemically-Activated LUciferase gene eXpression cell bioassay system) assay for dioxin-like chemicals.
In 2004 XDS was awarded a U.S. patent (6,720,431 B2) for their novel method of separation of dioxins/furans and dioxin-like PCB’s for XDS-CALUX analysis.
In July 2006, the LUMI-CELL ER bioassay system completed ICCVAM’s protocol standardization study, also know as the U.S. pre-validation study.
In March of 2007 the LUMI-CELL ER bioassay system started the international validation study with ICCVAM, ECVAM, and JaCVAM.
In 2007, the EPA’s Office of Solid Waste (OSW) Organic Methods Workgroup formally reviewed and approved the XDS-CALUX technology (EPA Method #4435) for inclusion into Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, also known as SW-846.